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a b s t r a c t
Aplastic anemia (AA) is a marrow failure syndrome mediated by aberrant T-cell subsets. Mesenchymal
stem cells (MSCs) play an important role in maintaining immune homeostasis through modulating a variety
of immune cells. However, little is known about the immunomodulation potential of bone marrow MSCs
(BM-MSCs) in AA. Here, we reported that BM-MSCs from AA patients were reduced in suppressing the
proliferation and clonogenic potential of CD4+ T cells and the production of tumor necrosis factor-α (TNF-α)
and interferon-γ (IFN-γ), which was associated with decreased prostaglandin E2 (PGE2). Meanwhile, BM-
MSCs from AA patients were defective to promote CD4+CD25+FOXP3+ regulatory T cells expansion through
reduced transforming growth factor-β (TGF-β). No signiﬁcant difference between AA and normal BM-MSCs
was observed in affecting the production of interleukins (IL)-4, IL-10 and IL-17. Our data indicate that BM-
MSCs were impaired in maintaining the immune homeostasis associated with CD4+ T cells, which might
aggravate the marrow failure in AA.
Crown Copyright c© 2012 Published by Elsevier B.V.
1. Introduction
Aplastic anemia (AA) is mostly considered an immune-mediated
bonemarrow failure syndrome, characterized by hypoplasia and pan-
cytopenia with fatty bone marrow and reduced angiogenesis. Previ-
ous investigations have demonstrated that acquired AA is manifested
as abnormalities of hematopoietic stem/progenitors cells (HSCs/
HPCs) and hematopoietic microenvironment, which are mediated by
abnormal immunity [1]. T cell is themajor factormediating the patho-
genesis of acquired AA, which is involved with imbalanced CD4+ and
CD8+ T cells subpopulation. CD4+ T cells were commonly divided into
helper T lymphocyte (Th1), Th2, Th17 and CD4+CD25+ FOXP3+ regu-
latory T cells (Tregs). Th1 cells and cytotoxic T lymphocytes (CTLs) are
activatedwhile Tregs are deﬁcient, and Th2 cells are almost normal or
expanded in AA [3–7]. Aberrant immune cells directly and indirectly
destruct HSCs by secreting a variety of immune molecules including
tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and inter-
leukins (IL-2, 8, 12, 15, 17, 27) [1,8–10]. As a result, HSCs are severely
impaired to be disabled cells leading to hypoplasia and pancytopenia.
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Lots of evidence has hinted that AA might be a syndrome charac-
terized by stem/progenitor-cell disorders including HSCs/HPCs and
bone marrow mesenchymal stem cells (BM-MSCs).
Previous studies have demonstrated that HSCs/HPCs from AA pa-
tients are defective in multiple biological properties and functions
[11–13]. Besides the role of HSCs/HPCs in the process of hematopoi-
sis, BM-MSCs as the key precursor cells ofmarrowmicroenvironment
may also play an important role in the development of AA. MSCs
differentiate into a variety of stromal cells to constitute HSC niche,
which include endothelial cells, adipocytes, ﬁbroblasts, osteoblasts
and osteoclasts etc. MSCs and differentiated stromal cells support
hematopoiesis and regulate almost overall immune cells function to
maintain the hematopoietic and immune homeostasis [14]. MSCs can
modulate themajor immune cell functions including T, B, monocytes,
dendritic cells (DCs), nature killer cells (NKs) and neutrophils [16].
MSCs possess remarkable immunosuppressive properties on Th1 and
CTLs. MSCs inhibit the proliferation of T cells, IFN-γ and TNF-α se-
cretion by Th1 cells while promoting IL-10 production by Th2 cells
and the expansion of Tregs. However, it is controversial about the
immunomodulation ofMSCs on IL-4 and IL-17 production by Th2 and
Th17 cells [18].
Recently, sporadic research showed that MSCs from AA patients
had poor proliferation and deﬁcient immune suppression of MLR,
PHA-induced T cell activation and IFN-γ release [20]. T lymphocyte
is known to be the major executor of the adaptive immune response
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and the arch-criminal of hematopoiesis destruction in AA. During the
development of AA, Th1 and Th17 cells are expanded while Tregs are
reduced [7].However, it is still controversial about the levels and func-
tions of Th2 cells [3,7]. It is necessary to determinewhether BM-MSCs
contribute to the aberrant immunomodulation process mediated by
CD4+ T cells in AA.
Therefore, the present research was designed to elucidate the ef-
fect of BM-MSCs from AA patients on CD4+ T cells in order to ob-
tain more evidence for the marrow microenvironment failure in the
pathogenesis of AA. We found that BM-MSCs from AA patients were
reduced in suppressing the proliferation and clonogenic potential of
CD4+ T cells while promoting Tregs expansion. They were also defec-
tive to suppress the production of TNF-α and IFN-γ by CD4+ cells.
However, there was no signiﬁcant difference in regulating the pro-
duction of IL-4, IL-10 and IL-17. Our data have demonstrated that
BM-MSCs were abnormal in maintaining the CD4+ T cellular immune
homeostasis in AA.
2. Materials and methods
2.1. Patients and controls
We analyzed bone marrow samples from 15 patients with AA
(mean age 31 years, 8 men and 7 women), as well as from 11 healthy
controls (mean age 33 years, 6 men and 5 women). The diagnosis of
AA was established by morphological examination of bone marrow
and blood after exclusion of any other marrow failure syndromes,
such as paroxysmal nocturnal hemoglobinuria (PNH), myelodysplas-
tic syndrome (MDS) and congenital bone marrow failure syndromes
according to the international criteria [22]. All patients did not re-
ceive any speciﬁc therapy such as cyclosporine A and antithymocyte
globulin (ATG) before enrollment. Controls were healthy donors who
were also identiﬁed by morphology examinations of bone marrow
and blood.
2.2. Isolation and identiﬁcation of BM-MSCs
Bone marrow aspirates were taken from patients and healthy
donors with informed consent in accordance with the Institutional
Review Board of CAMS and PUMC. Bone marrow mononuclear cells
(BMMNCs) were isolated from samples using the Ficoll-Hypaque
(1.077 g/mL) (TianjinHaoyang BiologicalManufacture Co. Ltd., China)
density gradient centrifugation. Isolated BMMNCs were cultured in
Dulbecco’s Modiﬁed Eagle Medium: Nutrient Mixture F-12 (D-MEM/
F-12) (Gibco, Carlsbad, CA, USA) supplemented with 40% MCDB-201
(Sigma, St. Louis, USA), 2% fetal bovine serum (FBS) (Hyclone, Logan,
UT, USA), 1× insulin–transferrin–selenium (ITS) (Gibco, Carlsbad,
CA, USA), 10−8M dexamethasone (Sigma, St. Louis, USA), 100U/mL
penicillin/streptomycin, 2mM l-glutamine (Sigma, St. Louis, USA),
2 ng/mL human basic-ﬁbroblast growth factor (bFGF) and 10ng/mL
human EGF (PeproTech, Rocky Hill, NJ, USA). After 3 days, the cul-
ture medium was completely replaced and non-adherent cells were
removed. At about 80–85% conﬂuency, the adherent cells were de-
tached by 0.125% trypsin and 0.1% EDTA (Sigma, St. Louis, USA) and
replated at a 1:2dilutionunder the sameculture conditions. BM-MSCs
were identiﬁed by the surface markers with monoclonal antibodies
CD29 (MAR4), CD166 (3A6), CD44 (515), CD73 (AD2), CD49e (IIA1),
CD34 (581), CD90 (5E10), CD45 (HI30), CD105 (266), HLA-DR (G46–
6), isotypemAbs (BD Pharmingen, San Jose, CA, USA) using a FACScan
ﬂow cytometry (BD Biosciences, Mountain View, CA, USA). BM-MSCs
(P3) were stained with β-tubulin for the morphology examination
using a ﬂuorescence confocal microscopy (Leica TCS SP2, Leica Mi-
crosystems,Wetzlar, Germany).
2.3. Adipogenic and osteogenic differentiation potential of BM-MSCs
BM-MSCs (P4) were induced to differentiate into adipocytes and
osteoblasts. The induction medium for adipogenesis was Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM) (Gibco, Carlsbad, CA, USA) sup-
plementedwith 10% FBS, 10−6M dexamethasone, 0.5mM3-isobutyl-
1-methylxanthine, 10mg/mL insulin and 60µM indomethacin
(Sigma, St. Louis, USA). The induction medium for osteogenesis was
IMDM supplemented with 10% FBS, 10−7 M dexamethasone, 0.2mM
ascorbic acid 2-phosphate and 10mM glycerol 2-phosphate (Sigma,
St. Louis, USA). Three days later, the culture medium was completely
replaced. After the determined culture, the adipocytes were stained
with Oil Red O, and the osteoblasts with von Kossa and alkaline phos-
phatase assays (Sigma, St. Louis, USA) according to the protocols.
2.4. Co-culture of BM-MSCs and peripheral blood (PB)-derived CD4+ T
cells
Peripheral blood was obtained from healthy adult donors accord-
ing to the Institutional Review Board of CAMS and PUMC. Periph-
eral blood mononuclear cells (PBMNCs) were isolated using Ficoll-
Hypaque (1.077 g/mL) (Tianjin Haoyang Biological Manufacture Co.
Ltd., China). CD4+ T cells were puriﬁed by positive selectionwith anti-
CD4 mAb-conjugated microbeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) according to the manufacturer’s instructions. BM-
MSCs (P4) and CD4+ T cells were co-cultured (MSC:CD4+ T cell ra-
tio, 1:10) in the culture medium containing IMDM, 10% FBS, 100U/
mL penicillin/streptomycin and 2mM l-glutamine in the presence
of 5mg/mL PHA (Roche, Penzberg, Germany) and 5ng/mL of rIL-2
(PeproTech, Rocky Hill, NJ, USA) for 4 days.
2.5. Clonogenic and proliferation potential of CD4+ T cells
Clonogenic potential of CD4+ T cells was examined using an in-
verted microscope (OLYMPUS IX71S8F-2, Tokyo, Japan) after 4 days
culture. CD4+ T cells proliferation was measured by incorporation of
BrdU using cell proliferation ELISA assay after 4 days. CD4+ T cells
were seeded in triplicate in 96-well plates. The optical density (OD)
values were determined in triplicate against a reagent blank at a test
wave length of 450nm.
2.6. Cytokine enzyme-linked immunosorbent assay
Culture supernatants were harvested for cytokine determination
by enzyme-linked- immunosorbent assay (ELISA). The concentrations
of IFN-γ, TNF-α, IL-17A, IL-10, IL-4 andTGF-β (Neobioscience, Shang-
hai, China) and prostaglandin E2 (PGE2) (Cayman Chemicals, Ann Ar-
bor, Michigan, USA) were measured according to the manufacturer’s
instructions. Samples were run in duplicate.
2.7. Induction the expansion of Tregs
BM-MSCs (P4) and CD4+ T cells were co-cultured (MSC:CD4+ T cell
ratio, 1:10) in the culture medium containing IMDM, 10% FBS, 100U/
mL penicillin/streptomycin and 2mM l-glutamine in the absence or
presence of 300U/mL rIL-2 (PeproTech, Rocky Hill, NJ, USA) for 5
days. After 5 days of co-culture, nonadherent T cells were harvested
and evaluated for the proportion of Tregs with monoclonal antibod-
ies FITC-CD4, APC-CD25 and PE-FOXP3 antibodies (BD Pharmingen,
San Jose, CA, USA) using a FACScan ﬂow cytometer (BD Biosciences,
Mountain View, CA, USA).
2.8. Statistical analysis
Data were analyzed with the 15.0 SPSS software. Results are pre-
sented asmean ± SD. The statistical differences betweengroupswere
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Fig. 1. The representative for immnophenotype of BM-MSCs of healthy controls (n= 11) andAApatients (n= 15). The immnophenotype of BM-MSCswas assessedwithmonoclonal
antibodies CD45, HLA-DR (HLA-II), CD90, CD34, CD29, CD166, CD105, CD44, CD73 and CD49e using a FACScan ﬂow cytometry. All independent experiments were performed three
times. Abbreviation: AA, aplastic anemia.
evaluated by One-Way ANOVA and Student’s t test, deﬁned as a value
of P < 0.05, P < 0.01 and P < 0.001.
3. Results
3.1. Isolation and identiﬁcation of BM-MSCs
BM-MSCs were isolated and cultured from 15 AA patients and 11
healthy controls. BM-MSCs were harvested at passage 3 to analyze
the immunophenotype using ﬂow cytometry. As shown in Fig. 1, BM-
MSCs from both AA patients and healthy controls expressed CD105
(SH2), CD73 (SH3), CD90, CD29, CD44, CD49e, and CD166, but lack
expression of CD34, CD45 and HLA-DR (HLA-II). There was no signif-
icant difference of the expression of BM-MSCs markers between AA
patients and healthy controls (P > 0.05, data not shown). BM-MSCs
from either AA patients or healthy controls could form a monolayer
of bipolar spindle-like cells with awhirlpool-like array (Fig. 2A). After
induction with different conditional media, BM-MSCs could differen-
tiate into adipocytes and osteoblasts as detected by positive staining
of Oil Red O for adipogenic differentiation (Fig. 2B and C), Allizarin
Red, von Kossa and ALP for osteogenic differentiation (Fig. 2D, E and
F), respectively. Interestingly, BM-MSCs from AA patients were easily
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Fig. 2. The representative morphology and differentiation capacity of BM-MSCs from
AA patients and healthy controls. The morphology of BM-MSCs was shown after stain-
ing with β-tubulin (A). The adipogenic differentiation capacity of BM-MSCs detected
by untaining (B) and positive staining of Oil Red O (C). The osteogenic differentiation
capacity of BM-MSCs detected by positive staining of Allizarin Red (D), von Kossa (E)
and ALP (F). Scale bar = 200µm. Abbreviation: AA, aplastic anemia.
induced to differentiate into adipocyte lineage, but difﬁcultly induced
to differentiate into osteoblast lineage.
3.2. Inhibition of clonogenic and proliferation capacity of CD4+ T cells
by BM-MSCs
Previous studies in our laboratoryhave showed that umbilical cord
and fetal BM-derivedMSCsmodulate immune activities on different T
subpopulations [18,23]. And the cellular immunemediated by CD4+ T
cells hasbeen consideredas themajormechanismofHSCsdestruction
in acquired AA. Therefore, we examined the immune effect of BM-
MSCs on healthy peripheral blood-derived CD4+ T cells to elucidate
the immunomodulation capacity of BM-MSCs from AA patients. BM-
MSCs fromAApatients and healthy controlswere paired to co-culture
with PB CD4+ T cells sorted using microbeads from unrelated donors.
As shown in Fig. 3, the presence of BM-MSCs fromhealthy controls (C)
and AA patients (B) resulted in an obvious decrease in PHA-induced
clonogenic capacity of CD4+ T cells. But the inhibition by BM-MSCs
from AA patients was signiﬁcantly attenuated in comparison with
that of healthy controls. Meanwhile, the presence of BM-MSCs from
healthy controls also resulted in a statistically signiﬁcant decrease
in PHA-induced proliferation capacity of CD4+ T cells (P = 0.002).
The inhibition by BM-MSCs from AA patients (Fig. 3B and D) was
signiﬁcantly attenuated in comparison with that of healthy controls
(P = 0.046) (Fig. 3C and D). There was no signiﬁcant difference of
proliferation rate between group CD4 and group AA-MSC+CD4 (P =
0.232) (Fig. 3D).
3.3. Effects of BM-MSCs on the cytokines production by CD4+ T cells
The subpopulations of CD4+ T cells mostly exert their immune
functions by secreting a variety of immunemolecules. Recently, CD4+
T cells were divided into Th1, Th2, Th17 cells and Tregs according
to their functions. Therefore, we compared the production of TNF-
α, IFN-γ, IL-4, IL-10 and IL-17A by CD4+ T cells in the presence of
BM-MSCs to elucidate the immune effect of BM-MSCs on different T
cells subtypes such as Th1, Th2 and Th17 cells. We showed that both
BM-MSCs inhibited the production of TNF-α and IFN-γ by CD4+ T
cells (Fig. 4A and B) but promoted the production of IL-4 and IL-17A
by CD4+ T cells (Fig. 4C and E) (P < 0.01). However, there was no
signiﬁcant effect on IL-10 production (Fig. 4D). Interesting, there was
a signiﬁcant decrease in inhibiting TNF-α and IFN-γ production me-
diated by BM-MSCs from AA patients compared with that of healthy
Fig. 3. The inhibition of clonogenic and proliferation capacity of PB CD4+ T cells by BM-
MSCs. The representative for clonogenic capacity of CD4+ T cellswas examinedwithout
BM-MSCs (A), with BM-MSCs from AA patients (B) and healthy controls (C) using an
inverted microscope (n = 10). Scale bar = 500µm. The proliferation capacity of CD4+
T cells was determined by incorporation of BrdU using cell proliferation ELISA assay
(D). All data represented mean ± SD of triplicate of 10 independent experiments. The
signiﬁcance was shown as P < 0.05 and P < 0.01. N-MSC and BM-MSCs from healthy
controls. AA-MSC and BM-MSCs from apalstic anemia patients.
controls (P< 0.05) (Fig. 4A and B). There was no signiﬁcant difference
in the production of IL-4, IL-10 and IL-17A by CD4+ T cells between
AA patients and healthy controls (P > 0.05) (Fig. 4C–E). We further
showed that PGE2 in the culture supernatant of BM-MSCs from AA
patients was decreased compared with that of healthy controls (P <
0.05) (Fig. 4F).
3.4. BM-MSCs from AA patients were defective in promoting the
expansion of Tregs.
Moreover, we compared the effect of BM-MSCs on the expansion
of CD4+CD25+ FOXP3+ population (Tregs). We showed that BM-MSCs
from healthy controls promoted the expansion of Tregs population
by rhIL-2 (Fig. 5A and C) (P < 0.01). But, BM-MSCs from AA patients
were defective in inducing Tregs expansion (5.82 ± 2.56%) compared
with that of healthy controls (9.24 ± 1.61%) (P < 0.05). To demon-
strate the possible mechanism, we examined TGF-β levels secreted
byBM-MSCs and found that therewas a relevant decrease inAAgroup
(247.66 ± 117.23pg/ml) than healthy controls (485.41 ± 99.27pg/
ml) (P < 0.05) (Fig. 5B).
4. Discussion
The present study was aimed to elucidate the effect of BM-MSCs
from AA patients on CD4+ T cells and obtain more evidence for the
marrow microenvironment failure in AA. We found that BM-MSCs
from AA patients were reduced in suppressing the proliferation and
clonogenic potential of CD4+ T cells and the production of TNF-α and
IFN-γ by CD4+ T cells, which might be associated with decreased
PGE2. Meanwhile, BM-MSCs from AA patients were defective in pro-
moting Tregs expansion through reduced TGF-β. However, therewas
no signiﬁcant difference between normal and AA BM-MSCs in their
ability to affect the production of interleukins IL-4, IL-10 and IL-17 by
CD4+ T cells.
Both HSCs and MSCs are key stem cells responsible for normal
hematopoiesis. HSCs maintain hematopoiesis through self-renewal
and differentiation. MSCs, as non-hematopoietic stem cells, support
hematopoiesis and maintain the immune homeostasis in the bone
marrow. Previous investigations have demonstrated that HSCs were
damaged by T cells-mediated immune during the development of
AA. Various evidence showed that BM-MSCs in AA were also abnor-
mal when compared with healthy controls [20]. Transplantation of
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Fig. 4. Effect of BM-MSCs on the secreted cytokines by CD4+ T cells. The production of
IFN-γ (A), TNF-α (B), IL-17A (C), IL-10 (D) and IL-4 (E) by CD4+ T cells in the presence
of BM-MSCs from AA patients and healthy controls was determined by ELISA. The
concentration of PGE2 (F) in the culture supernatant of BM-MSCs was also determined
by ELISA. All data representedmean ± SD of triplicate of 10 independent experiments.
The signiﬁcance was shown as P < 0.05, P < 0.01 and P < 0.001. N-MSC and BM-MSCs
from healthy controls. AA-MSC and BM-MSCs from apalstic anemia patients.
Fig. 5. Effect of BM-MSCs on the expansion of Tregs. The proportion of Tregs in the
presence of BM-MSCs from AA patients and healthy controls was determined using a
FACScan ﬂow cytometer (A) and (C). The production of TGF-β by BM-MSCs from AA
patients and healthy controls was determined by ELISA (B). All data represented mean
± SD of triplicate of 10 independent experiments. The signiﬁcance was shown as P <
0.05 and P < 0.01. N-MSC and BM-MSCs from healthy controls. AA-MSC and BM-MSCs
from apalstic anemia patients.
MSCs can enhance the reconstruction of hematopoiesis and immune
systems of AA patients [24–26]. However, it remains unclear about
the comprehensive abnormality of BM-MSCs in AA.
Immune regulation is oneof themost important functionsofMSCs.
In recent years, MSCs have attracted signiﬁcant attention from basic
and clinical investigators because of their effective immunomodula-
tion potential. MSCs affect a variety of immune cells maturation and
functions. Especially, they exhibit remarkable regulation on CD4+ T
cells including Th1, Th2, Th17 and Tregs to maintain the immune bal-
ance. MSCs inhibit the proliferation of T cells, IFN-γ and TNF-α se-
cretion by Th1 cells while promote IL-10 production by Th2 cells and
the expansion of Tregs. Acquired AA is considered as T cell-mediated
marrow failure. Abnormal CD4+ T cells population and secreted cy-
tokines play very important roles in the destruction of HSCs/HPCs.
During the development of AA, Th1 and Th17 cells are expanded and
activated [7]. A variety of immunemolecules including IFN-γ, TNF-α
and ILs (IL-2, 8, 12, 15, 17, and 27) compose a cytokine network to
destruct stem/progenitor cells as well as HSCs/HPCs andMSCs [1,10].
Inversely, deﬁcient Tregs diminish the capacity of immune regulation
and the support of hematopoiesis [4,7]. It is obvious that aberrant
CD4+ T cells immunity in AA is in accordance with the regulation of
MSCs on CD4+ T cells. Therefore, we co-cultured BM-MSCs together
with PB-derived CD4+ cells to demonstrate whether deﬁcient MSCs
aggravate the immune imbalance in AA.
In the present study, we found that BM-MSCs from AA patients
were reduced in suppressing the proliferation and clonogenic poten-
tial of CD4+ T cells. BM-MSCs from AA patients were also defective in
inhibiting the production of TNF-α and IFN-γ by CD4+ T cells while
there was no signiﬁcant difference in modulating the production of
IL-4, IL-10 and IL-17A comparedwithhealthy controls. Therefore, BM-
MSCs could not inhibit the over-production by activated CD4+ T cells.
Finally, excessive TNF-α and IFN-γ accumulated in the bonemarrow
to further destruct the normal hematopoiesis. Previous studies have
demonstrated that BM derived MSCs and CD4+ T cells might interact
with each other through direct contact and a variety of molecules
such as PGE2, galectin-1, indoleamine 2,3 dioxygenase (IDO), nitric
oxide (NO), HLA-5G and TGF-β [23,27–30]. PGE2 and galectin-1 are
of great importance in the immunosuppresive process of MSCs. Re-
searches inour laboratory showed that PGE2 played important roles in
the immunosuppression of various MSCs on Th1 and the production
of TNF-α and IFN-γ. In order to demonstrate the possible mecha-
nism, we compared and found that PGE2 in the culture supernatant
of BM-MSCs from AA patients was signiﬁcantly decreased. We in-
ferred that these defects might be associated with decreased PGE2. In
addition, BM-MSCs from AA patients were also defective in promot-
ing Tregs expansion. In AA, reduced total number of Tregs could not
maintain the immune homeostasis and might aggravate the immune
destruction of hematopoiesis. Interestingly, TGF-β as a key cytokine
in inducing Tregs expansionwas decreased in the culture supernatant
of BM-MSCs from AA patients. Reduced TGF-β might be one of the
possible factors for reduced contribution of BM-MSCs to Tregs expan-
sion. In short, BM-MSCs from AA patients were limited either in the
suppression of Th1 (TNF-α and IFN-γ) or in the contribution on Tregs
expansion, but have no obvious defect on the regulation of Th2 (IL-4
and IL-10) and Th17 (IL-17A) cells. As a result, the polarization of Th1
and increased IFN-γ and TNF-αmight destruct the hematopoiesis in
the process of AA. When BM-MSCs were destructed to be defective,
bone marrow suffered more severe loss in maintaining the immune
homeostasis which would further aggravate the aberrant immunity
in AA. Maybe our data also provides one of the key persuasive anno-
tations for the effective MSC transplantation in AA.
In summary, the present study demonstrated that BM-MSCs from
AA patients were impaired in immunomodulation ability on CD4+ T
cells,whichmight causemore severe imbalanceof immune regulation
and aggravate the bone marrow failure. Meanwhile, out data suggest
that transplantation ofMSCs alone or in combinationwithHSCs could
be an effective therapeutic strategy for AA in the future.
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